NeuroMetrix back in NASDAQ’s good graces, hits diabetes market with new test


A 1-for-6 reverse stock split worked out for NeuroMetrix Inc. (NSDQ:NUROD), which said today that it’s back in the good graces of the NASDAQ exchange, and announced a new product launch for the diabetes market.

The Waltham, Mass.-based company, a former high flier on Wall Street, has fallen back to earth after hitting a high-water mark of $39.35 per share in August 2006.

When share prices fell below $1 apiece for 30 consecutive days last year, the stock exchange warned of a potential delisting if share prices stayed below the $1 threshold.

That prompted NeuroMetrix, which makes equipment to test nerve conduction, to ask its shareholders to approve the reverse split back in April. Earlier this month the company pulled the trigger on the split and its share price responded. NURO shares have bounced between $1.71 and $2.30 since the Sept. 2 split and were trading at $1.72 as of about 10:50 today, down 2.8 percent on the day.

Sign up to get our free newsletters delivered straight to your inbox

NeuroMetrix also said it shipped the first of its new product line aimed at the diabetes market. Its NC-stat DPNCheck point-of-care test is designed to evaluate systemic neuropathies such as diabetic peripheral neuropathy.

“NeuroMetrix believes that the NC-stat DPNCheck test may address the unmet medical need for better, cost-effective approaches to detecting and monitoring DPN,” according to a press release. “Commercial shipment represents the culmination, on schedule, of a year-long product development effort to modify the company’s NC-stat technology to the focused evaluation of the sural nerve. In tandem, the development effort resulted in substantial cost reductions that enable an innovative approach to commercial deployment of this important advance in diabetes care.”

NeuroMetrix is also co-developing an over-the-counter version of the NC-Stat test for DPN, along with Japan’s Nipro Corp. (TYO:8086).

Early this year the company said it planned to stop supporting its workhorse NC-stat device for neurodiagnostics and pursue its use for diabetic indications instead. The general purpose NC-stat suffered a setback it never got over after the Centers for Medicare and Medicaid Services cut reimbursement rates for procedures using the device.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply